FcRI Inhibitors
2 drugsAbout FcRI
FcεRI is the high-affinity receptor for IgE, crucial in allergic reactions. When bound by IgE and cross-linked by allergens, it triggers mast cell and basophil activation, releasing mediators that cause allergic disease symptoms.
FcεRI is a significant target in respiratory therapeutic areas, though no genetic evidence directly links it to specific diseases. Its role in the inflammatory cascade associated with asthma and allergic rhinitis makes it therapeutically relevant.
Two FDA-approved drugs, XOLAIR (omalizumab) and OMLYCLO, target FcεRI. These drugs are biologics, including one antibody and one other biologic, developed by Roche and CELLTRION INC for respiratory indications.
Top FcRI Drugs
The competitive landscape includes Roche and CELLTRION INC, each with approved drugs.
Limited number of players suggests opportunity for new entrants with differentiated FcεRI therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline